Licht J D, Mazanet R, Loehrer P J, Gonin R, Antman K H
Division of Clinical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.
Cancer Chemother Pharmacol. 1994;34(1):79-80. doi: 10.1007/BF00686117.
Intravenous-bolus etoposide has modest activity in sarcomas when given daily for 3-5 days. Low frequent doses theoretically inhibit topoisomerase II activity over a longer duration and have been reported to have increased activity in small-cell lung cancer. A phase I trial of oral etoposide resulted in partial responses in two patients with soft-tissue sarcomas. To estimate more accurately the response rate for daily oral etoposide in sarcomas, we treated 25 patients with 50 mg/m2 per day by mouth for 21 days every 4 weeks. Treatment-related toxicity included > or = grade 2 neutropenia in 6 of the 25 patients and thrombocytopenia in 3. One brief partial response was observed (4%; 95% confidence interval for true response rate, 0-11%). Disease stabilized in five patients for periods ranging from 3 to 18 months. At this dose and on this schedule, daily oral etoposide appears to have little activity against soft-tissue sarcomas.
静脉推注依托泊苷在肉瘤中每日给药3 - 5天时具有一定活性。理论上低频率剂量可在更长时间内抑制拓扑异构酶II活性，且据报道在小细胞肺癌中活性有所增加。一项口服依托泊苷的I期试验使两名软组织肉瘤患者出现部分缓解。为更准确地评估每日口服依托泊苷在肉瘤中的缓解率，我们对25例患者每4周口服50mg/m²，持续21天。治疗相关毒性包括25例患者中有6例出现≥2级中性粒细胞减少，3例出现血小板减少。观察到1例短暂部分缓解（4%；真实缓解率的95%置信区间为0 - 11%）。5例患者病情稳定3至18个月。在此剂量和方案下，每日口服依托泊苷对软组织肉瘤似乎几乎没有活性。
